In this study, we demonstrate that GHRH antagonists MIA-602 and MIA-690 not only exert individual inhibitory effects but also enhance the sensitivity of NSCLC cell lines and primary NSCLC cells to radiation therapy. Here, GHRH is linked to non-small cell lung carcinoma.